What Cygenex does

Cygenex is a precision medicine company founded in 2021 and headquartered in San Diego, California (16870 W. Bernardo Drive, Suite 400). It delivers pharmacogenomic (PGx) DNA testing, AI-driven predictive risk analytics, and end-to-end medical management solutions. The company targets self-insured employer groups, third-party administrators (TPAs), stop-loss carriers, managing general underwriters (MGUs), healthcare brokers, captive groups, and pharmacy benefit managers (PBMs), addressing adverse drug reactions, trial-and-error prescribing, and the roughly $1.2 trillion in annual employer healthcare spending — particularly the 20% of high-risk members who typically consume 80-85% of costs.

The technology stack is anchored by two AI-driven platforms: the Precision Insights AI Platform, which sits on top of a patent-pending Proprietary Risk Stratification Software that data-mines patient records against CPIC and FDA guidelines to identify candidates for testing, and the CyPHR AI Engine (launched April 2026), an AI health assistant that translates genetic and medication data into real-time clinical guidance. Both run on Microsoft Azure and are HIPAA and GINA compliant. Cygenex is lab-agnostic and designed to integrate with any laboratory, any PBM, and any TPA or care management platform. Its testing portfolio includes CyPharmacogenetics, CyACMG 73, CyRenew, CyCancer, and CyDementia, supported by a network of licensed genetic counselors and pharmacists across all 50 states.

The company generates revenue through Per Employee Per Month (PEPM) and Per Member Per Month (PMPM) subscription contracts, supplemented by case-based and outcome-based billing aligned to measurable plan savings, plus one-time fees on direct genetic test sales. Go-to-market combines direct enterprise field sales with channel distribution through healthcare brokers, TPAs, stop-loss carriers, captive groups, and joint GTM partnerships with Trinity Marketing Services (announced November 2025) and Blackwell Captive Solutions (announced September 2025); a Shopify-based storefront and kit-registration portal provide a direct-to-consumer channel. Cygenex has been recognized by the American Pharmacogenomics Association as the #1 PGx platform provider for TPAs, brokers, and self-insured employer groups, and by The Silicon Review as one of its 30 Leading Companies of the Year 2025.

Name

Cygenex

Legal name

Cygenex

Website

https://cygenex.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Cygenex is a US-based precision medicine company providing AI-driven pharmacogenomic testing, predictive risk analytics, and end-to-end health management solutions for self-insured employers, TPAs, stop-loss carriers, MGUs, brokers, captive groups, and PBMs.

Ownership category

akta.pro rank

Product category

Precision Medicine Software

NAICS

Software Publishers (5132), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)

akta.pro primary industry

Pharmacogenomics (PGx) Decision Support (HLAAANAB)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools (HLACAKAH), Pharmacogenomics-Informed Medication Optimization Support (HSABALAO)

Keywords

• Pharmacogenomics testing
• Precision medicine platform
• Genetic testing services
• Risk stratification software
• Healthcare data analytics

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. PEPM/PMPM Subscription: Cygenex offers flexible contracting models including Per Employee Per Month (PEPM) and Per Member Per Month (PMPM) billing. Pricing is structured to align with measurable ROI and plan savings. This is the primary recurring revenue model targeting self-funded employer groups, TPAs, and stop-loss carriers.
2. Case-based / Outcome-based Billing: Cygenex offers case-based or outcome-based billing models in addition to recurring subscription. Pricing is structured to align with measurable ROI and plan savings, supporting outcome-based performance contracting.
3. Genetic Testing Services: Revenue generated from pharmacogenomic (PGx) DNA testing services delivered through the end-to-end platform, including swab coordination, genetic counseling, and report delivery.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Cygenex provides AI-driven precision medicine solutions that combine pharmacogenomic (PGx) DNA testing with proprietary risk stratification software and analytics. The platform identifies high-risk individuals within employer populations, recommends personalized medication strategies, and delivers end-to-end workflow management from genetic testing through report delivery, provider engagement, PBM integration, and ongoing adherence monitoring. The flagship CyPHR AI Engine translates individual genetic data into real-time clinical guidance for patients and providers.

Product overview

Cygenex is a precision medicine platform built on a unified architecture with a core AI-driven technology layer (Precision Insights, Risk Stratification Software) powering multiple product lines. The flagship offering is the CyPHR AI Engine, an AI-powered health assistant that translates genetic data into real-time clinical guidance. Supporting this are pharmacogenomic (PGx) testing services including DNA/PGx Testing, and specialized genetic tests including CyACMG 73, CyRenew, CyCancer, CyDementia, and CyPharmacogenetics. All offerings are delivered through an End-to-End Solution platform that manages the complete workflow from testing through provider engagement and monitoring. Genetic Counseling Services provides ongoing patient support across all testing products.

Differentiator

Problem solved

Functional benefit

Products and services

• Precision Insights AI-driven platform leveraging proprietary algorithms to identify individuals who will benefit from personalized medication strategies, enabling targeted interventions and delivering data-driven personalized recommendations to improve patient care for employer groups, TPAs, and stop-loss carriers.
• CyPHR AI Engine (Cygenex Precision Health Response) AI-powered health assistant that translates individual genetic data into real-time clinical guidance for patients and healthcare providers, integrating DNA data with current medications to identify potential drug interactions and risks.
• Proprietary Risk Stratification Software Patent-pending software that assesses health risk and identifies high-risk individuals using CPIC and FDA guidelines to determine who would benefit most from genetic testing, integrating with existing case management workflows.
• DNA/PGx Testing Pharmacogenomics (PGx) DNA testing to identify the right drug for the right individual at the right dosage the first time, reducing adverse drug reactions and optimizing medication outcomes.
• End-to-End Solution Platform Comprehensive platform managing the entire process from employee selection and genetic testing through report delivery, provider engagement, PBM integration, aggregate reporting, and ongoing monitoring of medication adherence.
• CyPharmacogenetics Test Genetic test evaluating how an individual's genetic makeup affects their response to certain medications, helping determine if they are on the right drug at the right dosage.
• CyACMG 73 Genetic test evaluating 73 genes known to be markers for certain diseases, used to determine whether an individual is at risk of developing specific genetic disorders.
• CyRenew Genetic test focused on healthy aging, providing insights into predictive markers for age-related health conditions.
• CyCancer Hereditary cancer genetic test identifying genetic predispositions to various cancer types.
• CyDementia Genetic test examining predictive markers for Parkinson's Disease, Alzheimer's Disease, and Dementia risk.
• Genetic Counseling Services Network of licensed genetic counselors and pharmacists across all 50 states providing ongoing guidance and support throughout the genetic testing process, helping patients understand their results.

Quantifiable outcome

• Up to 95% reduction in error compared to manual health tracking
• +10 more outcomes

Named customers1 record

Segments9 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Trinity Marketing ServicescoreGTM or Marketing Partner · 18 November 2025Two-year partnership announced November 2025 between Cygenex and Trinity Marketing Services to incorporate PGx testing and predictive analytics into health strategies. Trinity offers Cygenex's PGx platform to employer groups to help members receive genetically informed medication guidance, reducing trial-and-error prescribing, improving safety, and supporting quicker recovery times. Collaboration aims to enhance trust and efficiency in employer health benefits through data-driven solutions.
• Blackwell Captive SolutionscoreGTM or Marketing Partner · 29 September 2025Partnership announced September 2025 to bring Cygenex's genetic testing and predictive health analytics to the B.Well Edge portfolio. Together the companies provide employers with smarter early risk detection, actionable insights for employees, and reduced healthcare costs. Blackwell is a medical stop-loss captive committed to helping employers bend the healthcare cost curve through proactive cost-containment strategies.
• Health Wellness AlliancesupportingStrategic or Co-development PartnerCygenex partners with Health Wellness Alliance to deliver personalized genetic medicine. Health Wellness Alliance is powered by Cygenex's DNA testing capabilities. The partnership focuses on personalized wellness for consumers through Cygenex's genetic testing platform.
• MicrosoftsupportingTechnology or IntegrationCygenex's CyPHR AI Engine is built on Microsoft's secure cloud infrastructure. This technology partnership provides the secure, scalable cloud backbone for Cygenex's HIPAA and GINA compliant precision health platform.

Scale indicators14 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Genomind: Pharmacogenomics testing company focused on mental health medication selection; offers PGx decision support to clinicians and health systems, directly overlapping Cygenex's PGx testing and clinical guidance offering.
• Dynamic DNA Labs: PGx testing laboratory providing pharmacogenomic reports to clinicians and employer wellness programs; directly comparable genetic testing menu and customer base to Cygenex.
• RxGenomix: PGx clinical decision support company delivering pharmacogenomic insights to health systems, payers, and providers; shares Cygenex's focus on embedding PGx guidance into medication management workflows.
• Molecular Testing Labs: Clinical laboratory offering pharmacogenomic and molecular diagnostic testing with clinician-facing reports; comparable as a PGx testing provider serving similar employer and provider channels.

Emerging players

• Color Health: Population-scale genetic testing and risk assessment platform serving employers, health plans, and clinicians; emerging competitor in employer-channel genetic testing with comparable population health angle.
• LetsGetChecked: Direct-to-consumer and employer-focused at-home testing platform including genetic and wellness tests; comparable as an alternative channel for distributing genetic testing to consumers and employer populations.
• GeneDx: Genomics company offering hereditary disease and rare disease genetic testing with AI-enabled interpretation; adjacent competitor as a tech-forward genetics platform targeting clinicians and payers.

Broad incumbents

• Quest Diagnostics: National clinical laboratory offering pharmacogenomic and genetic testing within a broad menu; competes in PGx but does not specialize in self-funded employer channels the way Cygenex does.
• Labcorp: Large diagnostic laboratory network providing PGx and genetic testing as part of a broad clinical services portfolio; relevant incumbent comparable for lab testing infrastructure and test menu.
• Myriad Genetics: Established genetic testing company offering hereditary cancer, pharmacogenomic, and other DNA tests to clinicians and health systems; broader portfolio but overlaps on PGx and risk-prediction genetic testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gene-tox-lab-solutions

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cygenex